Crandall Mark A, Bradley David J, Packer Douglas L, Asirvatham Samuel J
Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clin Proc. 2009 Jul;84(7):643-62. doi: 10.1016/S0025-6196(11)60754-4.
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Its increasing prevalence, particularly among the elderly, renders it one of the most serious current medical epidemics. Several management questions confront the clinician treating a patient with AF: Should the condition be treated? Is the patient at risk of death or serious morbidity as a result of this diagnosis? If treatment is necessary, is rate control or rhythm control superior? Which patients need anticoagulation therapy, and for how long? This review of articles obtained by a search of the PubMed and MEDLINE databases presents the available evidence that can guide the clinician in answering these questions. After discussing the merits of available therapy, including medications aimed at controlling rate, rhythm, or both, we focus on the present status of ablative therapy for AF. Catheter ablation, particularly targeting the pulmonary veins, is being increasingly performed, although the precise indications for this approach and its effectiveness and safety are being actively investigated. We briefly discuss other invasive options that are less frequently used, such as pacemakers, defibrillators, left atrial appendage closure devices, and the surgical maze procedure.
心房颤动(AF)是临床实践中最常见的心律失常。其患病率不断上升,尤其是在老年人中,使其成为当前最严重的医学流行病之一。治疗房颤患者的临床医生面临几个管理问题:这种情况是否应该治疗?由于这一诊断,患者是否有死亡或严重发病的风险?如果需要治疗,心率控制还是节律控制更优?哪些患者需要抗凝治疗,以及需要多长时间?这篇通过检索PubMed和MEDLINE数据库获得的文章综述,展示了可指导临床医生回答这些问题的现有证据。在讨论了现有治疗方法的优点,包括旨在控制心率、节律或两者的药物后,我们将重点放在房颤消融治疗的现状上。尽管针对这种方法的精确适应症及其有效性和安全性正在积极研究中,但导管消融,特别是针对肺静脉的消融,正在越来越多地进行。我们简要讨论其他较少使用的侵入性选择,如起搏器、除颤器、左心耳封堵装置和外科迷宫手术。